EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieStudienprotokoll

Treatment of age‐related macular degeneration with aflibercept using a treat, extend and fixed protocol; A 4‐year study of treatment outcomes, durability, safety and quality of life (An extension to the MATE randomised controlled trial)

Archana Airody iD, Heidi A Baseler, Julie Seymour, Victoria Allgar, Rajarshi Mukherjee, Louise Downey, Sushma Dhar-Munshi, Sajjad Mahmood, Konstantinos Balaskas, Theo Empeslidis, Rachel L W Hanson, Tracey Dorey und 3 weitere

Acta Ophthalmologica · 2024

DOI: 10.1111/aos.15774 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Acta Ophthalmologica, 2024. Verfasst von Archana Airody und 14 weiteren Autor:innen. Beteiligte Einrichtung: Academic Unit of Ophthalmology, York and Scarborough Teaching Hospitals NHS Foundation Trust, York, UK. Hauptthemen laut MEDLINE: Angiogenesis Inhibitors, Macular Degeneration. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 32 Literaturangaben. Gefördert von: Bayer PLC, Bayer, United Kingdom.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

Data are limited pertaining to the long‐term benefits of aflibercept treatment for neovascular age‐related macular degeneration (nAMD). The aim of this study was to provide outcomes, safety, durability and quality‐of‐life data with aflibercept using a modified treat, extend and fixed regime over 4 years.

Methods

Prospective, multicentre, single cohort observational study of treatment‐naïve nAMD participants treated with aflibercept as 2‐year extension of the MATE‐trial that compared early and late Treat‐and‐Extend for 2 years. Refracted ETDRS best corrected visual acuity (BCVA), central retinal thickness (CRT), treatment interval and adverse events were assessed. Quality‐of‐life was measured using the Macular Disease Dependent Quality of Life (MacDQoL) and Macular Disease Treatment Satisfaction Questionnaires (MacTSQ).

Results

Twenty‐six of 40 participants completing the MATE‐trial were enrolled with 20 completing the total 4‐year study. Mean BCVA was 60.7 at Month 0 and 64.8 ETDRS letters at Month 48 while CRT decreased from 423.7 μm to 292.2 μm. Five participants discontinued treatment due to inactivity. The mean number of treatments and visits for the remaining participants was 27 and 30.0, respectively, with treatment intervals extended to 12 weeks in four participants at Month 48. Both AMD‐specific QoL and treatment satisfaction remained stable between Months 0 and 48 and mean BCVA significantly correlated with AMD‐specific QoL scores at Months 12, 24 and 48.

Conclusions

Results suggest that BCVA can be maintained over 48 months when following a treat‐extend‐and‐fix regimen of aflibercept with intervals out to 12 weeks, while maintaining AMD‐specific QoL and treatment satisfaction.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Angiogenesis InhibitorsMacular DegenerationHumansRanibizumabQuality of LifeProspective StudiesVisual AcuityIntravitreal InjectionsTomography, Optical CoherenceReceptors, Vascular Endothelial Growth FactorTreatment OutcomeRecombinant Fusion ProteinsRandomized Controlled Trials as TopicObservational Studies as Topic

Stichwörter der Autor:innen

afliberceptdurabilityneovascular age‐related macular degenerationquality of lifesafety

Substanzen

Angiogenesis InhibitorsRanibizumabafliberceptReceptors, Vascular Endothelial Growth FactorRecombinant Fusion Proteins

Autor:innen und Institutionen

  • Academic Unit of Ophthalmology, York and Scarborough Teaching Hospitals NHS Foundation Trust, York, UK.
  • Hull York Medical School, University of York, York, UK.
  • Department of Psychology, University of York, York, UK.
  • Hull York Medical School, University of Hull, Hull, UK.
  • Peninsula Medical School, University of Plymouth, Plymouth, UK.
  • Leeds Teaching Hospital NHS Foundation Trust, Leeds, UK.

ORCID-Profile: Archana Airody, Richard P Gale

Förderung

  • Bayer PLC
  • Bayer, United Kingdom

Zitieren

APA

Airody, A., Baseler, H. A., Seymour, J., Allgar, V., Mukherjee, R., Downey, L., Dhar-Munshi, S., Mahmood, S., Balaskas, K., Empeslidis, T., Hanson, R. L. W., Dorey, T., Szczerbicki, T., Sivaprasad, S., & Gale, R. P. (2024). Treatment of age‐related macular degeneration with aflibercept using a treat, extend and fixed protocol; A 4‐year study of treatment outcomes, durability, safety and quality of life (An extension to the MATE randomised controlled trial). Acta Ophthalmologica. https://doi.org/10.1111/aos.15774

Vancouver

Airody A, Baseler HA, Seymour J, Allgar V, Mukherjee R, Downey L, et al. Treatment of age‐related macular degeneration with aflibercept using a treat, extend and fixed protocol; A 4‐year study of treatment outcomes, durability, safety and quality of life (An extension to the MATE randomised controlled trial). Acta Ophthalmologica. 2024. doi:10.1111/aos.15774

BibTeX
@article{Airody2024,
  author = {Airody, Archana and Baseler, Heidi A and Seymour, Julie and Allgar, Victoria and Mukherjee, Rajarshi and Downey, Louise and Dhar-Munshi, Sushma and Mahmood, Sajjad and Balaskas, Konstantinos and Empeslidis, Theo and Hanson, Rachel L W and Dorey, Tracey and Szczerbicki, Tom and Sivaprasad, Sobha and Gale, Richard P},
  title = {Treatment of age‐related macular degeneration with aflibercept using a treat, extend and fixed protocol; A 4‐year study of treatment outcomes, durability, safety and quality of life (An extension to the MATE randomised controlled trial)},
  journal = {Acta Ophthalmologica},
  year = {2024},
  doi = {10.1111/aos.15774}
}
Kostenlos starten →